Industry Research Reports

Home > Reports > Medical Care > Circulating Tumor Cells- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Circulating Tumor Cells- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published Date: 2025-01-16

Pages: 125 Pages

Report ld: 3479813

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Circulating Tumor Cells Market Size(US$)

CAGR 2025-2031

20.4%

Market Size,2031

USD 8,259

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 2,711 million

Market Forecast in 2031(Value)

US$ 8,259 million

CAGR

20.4%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.

This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells by region & country, by Type, and by Application.

The Circulating Tumor Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells.

MARKET SEGMENTATION

By Company

Menarini-Silicon Biosystems
Qiagen (Adnagen)
Advanced Cell Diagnostics
ApoCell
Epic Sciences
Greiner Bio-one GmbH
Cynvenio
SurExamBio-Tech
Fluxion Biosciences
Ikonisys
Hangzhou Watson Biotech
Biocept
CytoTrack
Guangzhou Wondfo Biotech
Celsee
Clearbridge Biomedics
ANGLE plc

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

CTC Enrichment
CTC Detection
CTC Analysis

Segment by Application

Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Circulating Tumor Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Circulating Tumor Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Circulating Tumor Cells Product Introduction

1.2 Global Circulating Tumor Cells Market Size Forecast (2020-2031)

1.3 Circulating Tumor Cells Market Trends & Drivers

1.3.1 Circulating Tumor Cells Industry Trends

1.3.2 Circulating Tumor Cells Market Drivers & Opportunity

1.3.3 Circulating Tumor Cells Market Challenges

1.3.4 Circulating Tumor Cells Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Circulating Tumor Cells Players Revenue Ranking (2024)

2.2 Global Circulating Tumor Cells Revenue by Company (2020-2025)

2.3 Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters

2.4 Key Companies Circulating Tumor Cells Product Offered

2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells

2.6 Circulating Tumor Cells Market Competitive Analysis

2.6.1 Circulating Tumor Cells Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 CTC Enrichment

3.1.2 CTC Detection

3.1.3 CTC Analysis

3.2 Global Circulating Tumor Cells Sales Value by Type

3.2.1 Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Circulating Tumor Cells Sales Value, by Type (2020-2031)

3.2.3 Global Circulating Tumor Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Breast Cancer

4.1.2 Prostate Cancer

4.1.3 Colorectal Cancer

4.1.4 Lung Cancer

4.1.5 Others

4.2 Global Circulating Tumor Cells Sales Value by Application

4.2.1 Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Circulating Tumor Cells Sales Value, by Application (2020-2031)

4.2.3 Global Circulating Tumor Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Circulating Tumor Cells Sales Value by Region

5.1.1 Global Circulating Tumor Cells Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Circulating Tumor Cells Sales Value by Region (2020-2025)

5.1.3 Global Circulating Tumor Cells Sales Value by Region (2026-2031)

5.1.4 Global Circulating Tumor Cells Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Circulating Tumor Cells Sales Value, 2020-2031

5.2.2 North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Circulating Tumor Cells Sales Value, 2020-2031

5.3.2 Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Circulating Tumor Cells Sales Value, 2020-2031

5.4.2 Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Circulating Tumor Cells Sales Value, 2020-2031

5.5.2 South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Circulating Tumor Cells Sales Value, 2020-2031

5.6.2 Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Circulating Tumor Cells Sales Value, 2020-2031

6.3 United States

6.3.1 United States Circulating Tumor Cells Sales Value, 2020-2031

6.3.2 United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Circulating Tumor Cells Sales Value, 2020-2031

6.4.2 Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Circulating Tumor Cells Sales Value, 2020-2031

6.5.2 China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.5.3 China Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Circulating Tumor Cells Sales Value, 2020-2031

6.6.2 Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Circulating Tumor Cells Sales Value, 2020-2031

6.7.2 South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Circulating Tumor Cells Sales Value, 2020-2031

6.8.2 Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Circulating Tumor Cells Sales Value, 2020-2031

6.9.2 India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

6.9.3 India Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Menarini-Silicon Biosystems

7.1.1 Menarini-Silicon Biosystems Profile

7.1.2 Menarini-Silicon Biosystems Main Business

7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions

7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.1.5 Menarini-Silicon Biosystems Recent Developments

7.2 Qiagen (Adnagen)

7.2.1 Qiagen (Adnagen) Profile

7.2.2 Qiagen (Adnagen) Main Business

7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions

7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.2.5 Qiagen (Adnagen) Recent Developments

7.3 Advanced Cell Diagnostics

7.3.1 Advanced Cell Diagnostics Profile

7.3.2 Advanced Cell Diagnostics Main Business

7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions

7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.3.5 Advanced Cell Diagnostics Recent Developments

7.4 ApoCell

7.4.1 ApoCell Profile

7.4.2 ApoCell Main Business

7.4.3 ApoCell Circulating Tumor Cells Products, Services and Solutions

7.4.4 ApoCell Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.4.5 ApoCell Recent Developments

7.5 Epic Sciences

7.5.1 Epic Sciences Profile

7.5.2 Epic Sciences Main Business

7.5.3 Epic Sciences Circulating Tumor Cells Products, Services and Solutions

7.5.4 Epic Sciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.5.5 Epic Sciences Recent Developments

7.6 Greiner Bio-one GmbH

7.6.1 Greiner Bio-one GmbH Profile

7.6.2 Greiner Bio-one GmbH Main Business

7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions

7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.6.5 Greiner Bio-one GmbH Recent Developments

7.7 Cynvenio

7.7.1 Cynvenio Profile

7.7.2 Cynvenio Main Business

7.7.3 Cynvenio Circulating Tumor Cells Products, Services and Solutions

7.7.4 Cynvenio Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.7.5 Cynvenio Recent Developments

7.8 SurExamBio-Tech

7.8.1 SurExamBio-Tech Profile

7.8.2 SurExamBio-Tech Main Business

7.8.3 SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions

7.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.8.5 SurExamBio-Tech Recent Developments

7.9 Fluxion Biosciences

7.9.1 Fluxion Biosciences Profile

7.9.2 Fluxion Biosciences Main Business

7.9.3 Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions

7.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.9.5 Fluxion Biosciences Recent Developments

7.10 Ikonisys

7.10.1 Ikonisys Profile

7.10.2 Ikonisys Main Business

7.10.3 Ikonisys Circulating Tumor Cells Products, Services and Solutions

7.10.4 Ikonisys Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.10.5 Ikonisys Recent Developments

7.11 Hangzhou Watson Biotech

7.11.1 Hangzhou Watson Biotech Profile

7.11.2 Hangzhou Watson Biotech Main Business

7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions

7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.11.5 Hangzhou Watson Biotech Recent Developments

7.12 Biocept

7.12.1 Biocept Profile

7.12.2 Biocept Main Business

7.12.3 Biocept Circulating Tumor Cells Products, Services and Solutions

7.12.4 Biocept Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.12.5 Biocept Recent Developments

7.13 CytoTrack

7.13.1 CytoTrack Profile

7.13.2 CytoTrack Main Business

7.13.3 CytoTrack Circulating Tumor Cells Products, Services and Solutions

7.13.4 CytoTrack Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.13.5 CytoTrack Recent Developments

7.14 Guangzhou Wondfo Biotech

7.14.1 Guangzhou Wondfo Biotech Profile

7.14.2 Guangzhou Wondfo Biotech Main Business

7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions

7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.14.5 Guangzhou Wondfo Biotech Recent Developments

7.15 Celsee

7.15.1 Celsee Profile

7.15.2 Celsee Main Business

7.15.3 Celsee Circulating Tumor Cells Products, Services and Solutions

7.15.4 Celsee Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.15.5 Celsee Recent Developments

7.16 Clearbridge Biomedics

7.16.1 Clearbridge Biomedics Profile

7.16.2 Clearbridge Biomedics Main Business

7.16.3 Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions

7.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.16.5 Clearbridge Biomedics Recent Developments

7.17 ANGLE plc

7.17.1 ANGLE plc Profile

7.17.2 ANGLE plc Main Business

7.17.3 ANGLE plc Circulating Tumor Cells Products, Services and Solutions

7.17.4 ANGLE plc Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)

7.17.5 ANGLE plc Recent Developments

8 Industry Chain Analysis

8.1 Circulating Tumor Cells Industrial Chain

8.2 Circulating Tumor Cells Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Circulating Tumor Cells Sales Model

8.5.2 Sales Channel

8.5.3 Circulating Tumor Cells Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Circulating Tumor Cells Market Trends

Table 2. Circulating Tumor Cells Market Drivers & Opportunity

Table 3. Circulating Tumor Cells Market Challenges

Table 4. Circulating Tumor Cells Market Restraints

Table 5. Global Circulating Tumor Cells Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Circulating Tumor Cells Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Circulating Tumor Cells Product Type

Table 9. Key Companies Time to Begin Mass Production of Circulating Tumor Cells

Table 10. Global Circulating Tumor Cells Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Circulating Tumor Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Circulating Tumor Cells Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Circulating Tumor Cells Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Circulating Tumor Cells Sales Market Share in Value by Type (2020-2025)

Table 17. Global Circulating Tumor Cells Sales Market Share in Value by Type (2026-2031)

Table 18. Global Circulating Tumor Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Circulating Tumor Cells Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Circulating Tumor Cells Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Circulating Tumor Cells Sales Market Share in Value by Application (2020-2025)

Table 22. Global Circulating Tumor Cells Sales Market Share in Value by Application (2026-2031)

Table 23. Global Circulating Tumor Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (%)

Table 27. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Circulating Tumor Cells Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Circulating Tumor Cells Sales Value, (2026-2031) & (US$ Million)

Table 31. Menarini-Silicon Biosystems Basic Information List

Table 32. Menarini-Silicon Biosystems Description and Business Overview

Table 33. Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions

Table 34. Revenue (US$ Million) in Circulating Tumor Cells Business of Menarini-Silicon Biosystems (2020-2025)

Table 35. Menarini-Silicon Biosystems Recent Developments

Table 36. Qiagen (Adnagen) Basic Information List

Table 37. Qiagen (Adnagen) Description and Business Overview

Table 38. Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions

Table 39. Revenue (US$ Million) in Circulating Tumor Cells Business of Qiagen (Adnagen) (2020-2025)

Table 40. Qiagen (Adnagen) Recent Developments

Table 41. Advanced Cell Diagnostics Basic Information List

Table 42. Advanced Cell Diagnostics Description and Business Overview

Table 43. Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions

Table 44. Revenue (US$ Million) in Circulating Tumor Cells Business of Advanced Cell Diagnostics (2020-2025)

Table 45. Advanced Cell Diagnostics Recent Developments

Table 46. ApoCell Basic Information List

Table 47. ApoCell Description and Business Overview

Table 48. ApoCell Circulating Tumor Cells Products, Services and Solutions

Table 49. Revenue (US$ Million) in Circulating Tumor Cells Business of ApoCell (2020-2025)

Table 50. ApoCell Recent Developments

Table 51. Epic Sciences Basic Information List

Table 52. Epic Sciences Description and Business Overview

Table 53. Epic Sciences Circulating Tumor Cells Products, Services and Solutions

Table 54. Revenue (US$ Million) in Circulating Tumor Cells Business of Epic Sciences (2020-2025)

Table 55. Epic Sciences Recent Developments

Table 56. Greiner Bio-one GmbH Basic Information List

Table 57. Greiner Bio-one GmbH Description and Business Overview

Table 58. Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions

Table 59. Revenue (US$ Million) in Circulating Tumor Cells Business of Greiner Bio-one GmbH (2020-2025)

Table 60. Greiner Bio-one GmbH Recent Developments

Table 61. Cynvenio Basic Information List

Table 62. Cynvenio Description and Business Overview

Table 63. Cynvenio Circulating Tumor Cells Products, Services and Solutions

Table 64. Revenue (US$ Million) in Circulating Tumor Cells Business of Cynvenio (2020-2025)

Table 65. Cynvenio Recent Developments

Table 66. SurExamBio-Tech Basic Information List

Table 67. SurExamBio-Tech Description and Business Overview

Table 68. SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions

Table 69. Revenue (US$ Million) in Circulating Tumor Cells Business of SurExamBio-Tech (2020-2025)

Table 70. SurExamBio-Tech Recent Developments

Table 71. Fluxion Biosciences Basic Information List

Table 72. Fluxion Biosciences Description and Business Overview

Table 73. Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions

Table 74. Revenue (US$ Million) in Circulating Tumor Cells Business of Fluxion Biosciences (2020-2025)

Table 75. Fluxion Biosciences Recent Developments

Table 76. Ikonisys Basic Information List

Table 77. Ikonisys Description and Business Overview

Table 78. Ikonisys Circulating Tumor Cells Products, Services and Solutions

Table 79. Revenue (US$ Million) in Circulating Tumor Cells Business of Ikonisys (2020-2025)

Table 80. Ikonisys Recent Developments

Table 81. Hangzhou Watson Biotech Basic Information List

Table 82. Hangzhou Watson Biotech Description and Business Overview

Table 83. Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions

Table 84. Revenue (US$ Million) in Circulating Tumor Cells Business of Hangzhou Watson Biotech (2020-2025)

Table 85. Hangzhou Watson Biotech Recent Developments

Table 86. Biocept Basic Information List

Table 87. Biocept Description and Business Overview

Table 88. Biocept Circulating Tumor Cells Products, Services and Solutions

Table 89. Revenue (US$ Million) in Circulating Tumor Cells Business of Biocept (2020-2025)

Table 90. Biocept Recent Developments

Table 91. CytoTrack Basic Information List

Table 92. CytoTrack Description and Business Overview

Table 93. CytoTrack Circulating Tumor Cells Products, Services and Solutions

Table 94. Revenue (US$ Million) in Circulating Tumor Cells Business of CytoTrack (2020-2025)

Table 95. CytoTrack Recent Developments

Table 96. Guangzhou Wondfo Biotech Basic Information List

Table 97. Guangzhou Wondfo Biotech Description and Business Overview

Table 98. Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions

Table 99. Revenue (US$ Million) in Circulating Tumor Cells Business of Guangzhou Wondfo Biotech (2020-2025)

Table 100. Guangzhou Wondfo Biotech Recent Developments

Table 101. Celsee Basic Information List

Table 102. Celsee Description and Business Overview

Table 103. Celsee Circulating Tumor Cells Products, Services and Solutions

Table 104. Revenue (US$ Million) in Circulating Tumor Cells Business of Celsee (2020-2025)

Table 105. Celsee Recent Developments

Table 106. Clearbridge Biomedics Basic Information List

Table 107. Clearbridge Biomedics Description and Business Overview

Table 108. Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions

Table 109. Revenue (US$ Million) in Circulating Tumor Cells Business of Clearbridge Biomedics (2020-2025)

Table 110. Clearbridge Biomedics Recent Developments

Table 111. ANGLE plc Basic Information List

Table 112. ANGLE plc Description and Business Overview

Table 113. ANGLE plc Circulating Tumor Cells Products, Services and Solutions

Table 114. Revenue (US$ Million) in Circulating Tumor Cells Business of ANGLE plc (2020-2025)

Table 115. ANGLE plc Recent Developments

Table 116. Key Raw Materials Lists

Table 117. Raw Materials Key Suppliers Lists

Table 118. Circulating Tumor Cells Downstream Customers

Table 119. Circulating Tumor Cells Distributors List

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

Table 123. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Circulating Tumor Cells Product Picture

Figure 2. Global Circulating Tumor Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)

Figure 4. Circulating Tumor Cells Report Years Considered

Figure 5. Global Circulating Tumor Cells Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Circulating Tumor Cells Revenue in 2024

Figure 7. Circulating Tumor Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. CTC Enrichment Picture

Figure 9. CTC Detection Picture

Figure 10. CTC Analysis Picture

Figure 11. Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 12. Global Circulating Tumor Cells Sales Value Market Share by Type, 2024 & 2031

Figure 13. Product Picture of Breast Cancer

Figure 14. Product Picture of Prostate Cancer

Figure 15. Product Picture of Colorectal Cancer

Figure 16. Product Picture of Lung Cancer

Figure 17. Product Picture of Others

Figure 18. Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 19. Global Circulating Tumor Cells Sales Value Market Share by Application, 2024 & 2031

Figure 20. North America Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)

Figure 21. North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

Figure 22. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 23. Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

Figure 24. Asia Pacific Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 25. Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031

Figure 26. South America Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 27. South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

Figure 28. Middle East & Africa Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 29. Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

Figure 30. Key Countries/Regions Circulating Tumor Cells Sales Value (%), (2020-2031)

Figure 31. United States Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 32. United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 33. United States Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 34. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 35. Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 36. Europe Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 37. China Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 38. China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 39. China Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 40. Japan Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 41. Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 42. Japan Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 43. South Korea Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 44. South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 45. South Korea Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 46. Southeast Asia Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 47. Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 48. Southeast Asia Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 49. India Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)

Figure 50. India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031

Figure 51. India Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031

Figure 52. Circulating Tumor Cells Industrial Chain

Figure 53. Circulating Tumor Cells Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Circulating Tumor Cells market? zhanKai

The top companies in the global Circulating Tumor Cells market are Menarini-Silicon Biosystems、Qiagen (Adnagen)、Advanced Cell Diagnostics.

What was the global market size of Circulating Tumor Cells in 2031? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Circulating Tumor Cells in 2025? shouQi

What is the annual compound growth rate of the global Circulating Tumor Cells market size from 2025 to 2031? shouQi

Related Reports

Global Circulating Tumor Cells Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Circulating Tumor Cells market size was US$ 2711 million in 2025 and is forecast to reach a readjusted size of US$ 9775 million by 2032 with a CAGR of 20.4% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 110
USD 4250.00
(Single User License)
Global Circulating Tumor Cells Market Research Report 2026
The global Circulating Tumor Cells market was valued at US$ 2711 million in 2025 and is anticipated to reach US$ 9775 million by 2032, at a CAGR of 20.4% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 134
USD 2900.00
(Single User License)
Circulating Tumor Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Circulating Tumor Cells was estimated to be worth US$ 2711 million in 2025 and is projected to reach US$ 9775 million, growing at a CAGR of 20.4% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 122
USD 3950.00
(Single User License)
Global Circulating Tumor Cells Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Circulating Tumor Cells market is projected to grow from US$ 2291 million in 2024 to US$ 8259 million by 2031, at a CAGR of 20.4% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 154
USD 4900.00
(Single User License)
Circulating Tumor Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published Date: 2025-08-05
Pages: 127
USD 3950.00
(Single User License)
Global Circulating Tumor Cells Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Circulating Tumor Cells market size was US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published Date: 2025-08-05
Pages: 109
USD 4250.00
(Single User License)
Global Circulating Tumor Cells Market Research Report 2025
The global market for Circulating Tumor Cells was valued at US$ 2291 million in the year 2024 and is projected to reach a revised size of US$ 8259 million by 2031, growing at a CAGR of 20.4% during the forecast period.
Published Date: 2025-08-05
Pages: 93
USD 2900.00
(Single User License)
Global Circulating Tumor Cells Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Circulating Tumor Cells was estimated to be worth US$ 2291 million and is forecast to reach approximately US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 157
USD 5900.00
(Single User License)
Global Circulating Tumor Cells Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Published Date: 2024-04-17
Pages: 176
USD 5600.00
(Single User License)
Global Circulating Tumor Cells Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Published Date: 2024-04-16
Pages: 167
USD 5900.00
(Single User License)

Global Circulating Tumor Cells Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Circulating Tumor Cells market size was US$ 2711 million in 2025 and is forecast to reach a readjusted size of US$ 9775 million by 2032 with a CAGR of 20.4% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 110
USD 4250.00 (Single User License)
Global Circulating Tumor Cells Market Research Report 2026
The global Circulating Tumor Cells market was valued at US$ 2711 million in 2025 and is anticipated to reach US$ 9775 million by 2032, at a CAGR of 20.4% from 2026 to 2032.
Published: 2026-01-04
Pages: 134
USD 2900.00 (Single User License)
Circulating Tumor Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Circulating Tumor Cells was estimated to be worth US$ 2711 million in 2025 and is projected to reach US$ 9775 million, growing at a CAGR of 20.4% from 2026 to 2032.
Published: 2026-01-04
Pages: 122
USD 3950.00 (Single User License)
Global Circulating Tumor Cells Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Circulating Tumor Cells market is projected to grow from US$ 2291 million in 2024 to US$ 8259 million by 2031, at a CAGR of 20.4% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 154
USD 4900.00 (Single User License)
Circulating Tumor Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published: 2025-08-05
Pages: 127
USD 3950.00 (Single User License)
Global Circulating Tumor Cells Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Circulating Tumor Cells market size was US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published: 2025-08-05
Pages: 109
USD 4250.00 (Single User License)
Global Circulating Tumor Cells Market Research Report 2025
The global market for Circulating Tumor Cells was valued at US$ 2291 million in the year 2024 and is projected to reach a revised size of US$ 8259 million by 2031, growing at a CAGR of 20.4% during the forecast period.
Published: 2025-08-05
Pages: 93
USD 2900.00 (Single User License)
Global Circulating Tumor Cells Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Circulating Tumor Cells was estimated to be worth US$ 2291 million and is forecast to reach approximately US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 157
USD 5900.00 (Single User License)
Global Circulating Tumor Cells Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Published: 2024-04-17
Pages: 176
USD 5600.00 (Single User License)
Global Circulating Tumor Cells Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Published: 2024-04-16
Pages: 167
USD 5900.00 (Single User License)